Agilent Technologies Releases New Target-Enrichment Solutions for Disease Research

04 Jun 2015

SANTA CLARA, California



Agilent Technologies Inc. (NYSE: A) today announced new additions to its market-leading SureSelect target-enrichment product family, which has already enabled researchers to identify more than 50 Mendelian disease-causing genes.

The new products-the SureSelect Human All Exon V6, V6+UTR and V6+COSMIC-are designed to address the current limitations of exome sequencing, giving researchers better coverage of hard-to-capture regions and providing deep coverage of relevant regions, with minimal sequencing.

By providing the most comprehensive, up-to-date exome design, these new products will enable researchers to delve deeper into both constitutional diseases and cancers.

“The SureSelect exome has been widely adopted in both clinical and translational research, and it has greatly enabled discovery of disease-causing genes," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "The Human All Exon V6 is an important addition to our strong NGS portfolio for constitutional disease research. It targets hard-to-capture and multi-mapping regions that had proven challenging for current exome products on the market. Along with SureSelectQXT, Agilent now provides the fastest hybridization-based enrichment solution, which will add great value in any research setting, enabling the identification of more variants with greatly reduced turnaround time and at lower sequencing cost.”

Thaysen noted that the new products cover more regions (including previously recognized gaps), increase the sensitivity of variant calling, and minimize false negative calls.

SureSelect Human All Exon V6+UTR adds untranslated regions of the exome for translational research, while V6+COSMIC adds data from the cancer research database known as the Catalogue Of Somatic Mutations In Cancer.

“This latest design, optimized to cover targeted regions in greater detail, can also be blended with any custom capture design, enabling an exome tailored for specific applications,” Thaysen said.

>> Back to News